MCAM and neoplasm: In vivo studies with SKOV3 xenografts demonstrated that vorinostat plus AA98 significantly reduced tumor volume and extended survival compared to single-agent treatments, underscoring the synergistic potential of targeting CD146 alongside HDACis.